[MUSIC PLAYING] JAMES LARNER: I'm James Larner, professor and chair of the Department of Radiation Oncology at UVA. I've been in the oncology business close to 30 years. What appealed to me about radiation oncology is it's the most active drug, if you consider radiation a drug. It's really a physical agent. It's a stretch to consider it a drug. But in addition to being highly active, we can target it precisely. So the patient benefit is extraordinary. One of the most frustrating problems in practicing oncology is resistance. With standard chemotherapy and targeted therapies, cancer cells almost always become resistant to these agents. On the other hand, cancer cells hardly ever become resistant to radiation. We have pioneered the use of stereotactic body radiation therapy for non-small cell lung cancer. We developed one of the original algorithms that predicts toxicity. That algorithm is now nationally used. We've treated several hundred patients with SBRT with extraordinarily good results. Cancer care has become incredibly complex in the last decade with different treatment options. At UVA, we have a weekly thoracic oncology team that meets and vigorously debates what is the optimal treatment for each patient.